Skip to content
  • 6,939 federal solicitations are open right now. How many of them are yours?
  • New solicitations are posted every day. The ones you never saw are the ones you cannot win.
  • Stop checking SAM.gov every morning. Let the contracts that fit your business come to you.
  • Tell Abierto what you sell in one sentence. AI reads every open solicitation for you.
  • Deadlines are short. Hear about a solicitation the day it is posted, not the week it closes.
  • Amendments move deadlines. Watch a solicitation and Abierto tells you when it changes.
  • See which contracts in your field are about to end, and who holds them today.
  • Plans from $39 a month. See your matches before you pay.
See plans
AbiertoGet started

Presolicitation

NOTICE OF INTENT TO SOLE SOURCE

75N96024Q00042

National Institutes of Health, National Institute of Health Niehs. Research and Development in Biotechnology (except Nanobiotechnology).

Response deadline

June 28, 2024 at 5:00 PM EDT

Closed 857 days ago. Posted June 13, 2024. Scheduled to archive July 13, 2024.

Get the next one like this from National Institutes of Health by email, the day it is posted.Find my opportunities

This one closed in 2024

18 like it are open now in research and development in biotechnology (except nanobiotechnology)

All 18 open in research and development in biotechnology (except nanobiotechnology)

Description

As published on SAM.gov.

The Division of Translational Toxicology (DTT) is an intramural division of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health. DTT uses traditional and cutting-edge approaches to better understand how factors in our environment may impact human health. Such approaches include identifying biomarkers of toxicity in different organs to evaluate the potential impacts of chemical agents of concern.

DTT requires support to generate robust summaries of transcriptional biomarkers of toxicity/disease in different tissues and organs. These summaries can then be used to characterize adversity in in vivo toxicity screens where gene expression is measured in a dose response format across multiple tissues. DTT is specifically interested in up/down-regulated organ/tissue transcriptional biomarkers of adversity (toxicity or disease) in mammalian models with an emphasis on rats.

Specific tissues for which biomarkers shall be identified and curated may include aorta, bone marrow, brain, cecum, colon, duodenum, epididymis, esophagus, eye, Harderian gland, heart, ileum, jejunum, kidney, liver, lung, lymph node, mammary gland, ovary, pancreas, parathyroid gland, peripheral nerve, pituitary, prostate, salivary gland, seminal vesicle, skeletal muscle, and skin.

Genes shall be identified with associated publications cited along with known eliciting agents (i.e., chemical treatments, dietary modifications, genetic models). Once a gene is identified, upstream mechanistic processes shall be curated to explain the response of each gene. The mechanistic curation shall ideally be organ/tissue specific but may also be more generalizable.

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. June 13, 2024

    Presolicitation

    Due June 28, 2024 at 5:00 PM EDT. SAM.gov, notice 5a9202a720d04056ab06855973cfa891

Points of contact